Venezuela

Reimbursed Care Access

Venezuela controls psychoactive compounds under a comprehensive national drug law (Ley Orgánica de Drogas) that implements the UN drug conventions; most classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, etc.) are classed as controlled substances with no routine therapeutic or reimbursed access outside of authorised research. Ketamine is used within the Venezuelan health system as an approved anesthetic and medical agent, but specialised psychiatric indications (including esketamine/Spravato or reimbursed psychedelic-assisted therapy) do not have an established, publicly documented nationwide reimbursement pathway.